PDF(Pubmed)
Abstract：
Antimicrobial peptides (AMPs) are molecules with an amphipathic structure that enables them to interact with bacterial membranes. This interaction can lead to membrane crossing and disruption with pore formation, culminating in cell death. They are produced naturally in various organisms, including humans, animals, plants and microorganisms. In higher animals, they are part of the innate immune system, where they counteract infection by bacteria, fungi, viruses and parasites. AMPs can also be designed de novo by bioinformatic approaches or selected from combinatorial libraries, and then produced by chemical or recombinant procedures. Since their discovery, AMPs have aroused interest as potential antibiotics, although few have reached the market due to stability limits or toxicity. Here, we describe the development phase and a number of clinical trials of antimicrobial peptides. We also provide an update on AMPs in the pharmaceutical industry and an overall view of their therapeutic market. Modifications to peptide structures to improve stability in vivo and bioavailability are also described.
摘要：
抗微生物肽(AMP)是具有两亲结构的分子,其使得它们能够与细菌膜相互作用。这种相互作用可以导致膜交叉和孔形成的破坏，最终导致细胞死亡。它们在各种生物体中自然产生，包括人类,动物,植物和微生物。在高等动物中，它们是先天免疫系统的一部分，它们抵消细菌的感染，真菌,病毒和寄生虫。AMP也可以通过生物信息学方法从头设计或从组合库中选择，然后通过化学或重组程序生产。自从他们发现,AMP作为潜在的抗生素引起了人们的兴趣，尽管由于稳定性限制或毒性，很少有人进入市场。这里,我们描述了抗菌肽的开发阶段和一些临床试验。我们还提供了有关制药行业AMP的最新信息，以及对其治疗市场的总体看法。还描述了对肽结构的修饰以改善体内稳定性和生物利用度。
